$BLCO

VON ESCHENBACH ANDREW C. sold $307K of BLCO

VON ESCHENBACH ANDREW C. sold 18,559 shares of Bausch & Lomb Corp (BLCO) at an average of $16.53 ($16.50–$16.58, $0.31M total) across 2 trades over 2026-08-06 to 2026-08-07.

Original reporting
SEC EDGAR · VON ESCHENBACH ANDREW C.
Published Aug 11, 2026, 12:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLCO
Neutral
low confidence
Mentioned
$BLCO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLCONeutralLow
01

Why it matters

The only new fact is the reported sale size, price range, and post-transaction holdings; it does not include guidance, earnings, litigation, or operational updates.

02

Market read

Traders may monitor insider selling as a sentiment input, but this filing alone is unlikely to change valuation without accompanying fundamentals.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing lacks any explanation for motive.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10, covering sales dated 2026-08-06 to 2026-08-07

Background

The article is an SEC Form 4 insider transaction for Bausch & Lomb Corp, reporting an open-market sale by a director.

Company-level read

Ticker impact

$BLCONeutralLow confidence
Context

Bausch & Lomb director Andrew C. Von Eschenbach sold 18,559 shares in open-market transactions at about $16.50 to $16.58.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 insider sales are common and the filing provides no new company-specific operational or financial information.

Market effects

Minimal, as the disclosure is company-specific insider activity without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the article notes no pre-arranged 10b5-1 plan, some traders may interpret the sale as higher conviction than typical, potentially adding short-term downside pressure.

Key entities

  • Bausch & Lomb Corp

    Subject of the Form 4 insider transaction disclosure.

  • Andrew C. Von Eschenbach

    Director who sold 18,559 shares in two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BLCOMed

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Bausch + Lomb (BLCO) and Bausch Health (BHC) announced Thomas J. Appio as interim CEO of Bausch + Lomb, replacing Brent Saunders. Appio will retain his role as Bausch Health CEO. The companies expect to raise full-year 2026 adjusted EBITDA guidance based on preliminary third-quarter results, with details to be provided on Oct. 28.

$BLCOLow

Bausch + Lomb Advances Oral Dry AMD Therapy BL1243 Following FDA Meeting

Bausch + Lomb (BLCO) reported progress in developing BL1243, an oral treatment for dry age-related macular degeneration (AMD), following a constructive FDA meeting. The FDA supported the proposed initial study design, which will assess the drug's safety and behavior in the body. If successful, BL1243 could offer a new treatment option for dry AMD patients. The company plans to initiate clinical trials in 2027.